loading page

Safety Analysis of High-Dose Methotrexate in Pediatric Non-Hodgkin Lymphomas
  • +3
  • Melanie Bernhardt,
  • Austin Brown,
  • Austyn Grim,
  • Michael Scheurer,
  • Nader El-Mallawany,
  • Nmazuo Ozuah
Melanie Bernhardt
Baylor College of Medicine

Corresponding Author:[email protected]

Author Profile
Austin Brown
Baylor College of Medicine
Author Profile
Austyn Grim
Texas Children's Hospital
Author Profile
Michael Scheurer
Baylor College of Medicine Department of Pediatrics
Author Profile
Nader El-Mallawany
Baylor College of Medicine
Author Profile
Nmazuo Ozuah
Baylor College of Medicine
Author Profile


High-dose methotrexate (HD-MTX) with rigorous supportive care is essential to the treatment of pediatric non-Hodgkin lymphomas (NHL). We describe the safety and tolerability of HD-MTX in patients with NHL treated at our center. In our cohort of 46 patients, the majority had at least one course of delayed clearance and/or creatinine elevation. Additionally, more than one-third of patients experienced an episode of grade ≥3 mucositis. Creatinine elevations and delayed clearance were independently associated with subsequent grade ≥3 mucositis. We advocate for greater availability of methotrexate monitoring to allow dose escalation of this essential modality around the world.
09 Mar 2022Submitted to Pediatric Blood & Cancer
09 Mar 2022Submission Checks Completed
09 Mar 2022Assigned to Editor
10 Mar 2022Reviewer(s) Assigned
16 Apr 2022Review(s) Completed, Editorial Evaluation Pending
16 Apr 2022Editorial Decision: Revise Major
31 Jul 2022Submission Checks Completed
31 Jul 2022Assigned to Editor
31 Jul 20221st Revision Received
01 Aug 2022Review(s) Completed, Editorial Evaluation Pending
01 Aug 2022Editorial Decision: Accept
Nov 2022Published in Pediatric Blood & Cancer volume 69 issue 11. 10.1002/pbc.29940